IDEXX Laboratories Statistics
Share Statistics
IDEXX Laboratories has 81.88M shares outstanding. The number of shares has increased by -0.9% in one year.
| Shares Outstanding | 81.88M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.34% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 81.07M |
| Failed to Deliver (FTD) Shares | 1.82K |
| FTD / Avg. Volume | 0.3% |
Short Selling Information
The latest short interest is 2.08M, so 2.54% of the outstanding shares have been sold short.
| Short Interest | 2.08M |
| Short % of Shares Out | 2.54% |
| Short % of Float | 2.56% |
| Short Ratio (days to cover) | 3.32 |
Valuation Ratios
The PE ratio is 54.56 and the forward PE ratio is 35.63. IDEXX Laboratories 's PEG ratio is 2.14.
| PE Ratio | 54.56 |
| Forward PE | 35.63 |
| PS Ratio | 12.59 |
| Forward PS | 8.3 |
| PB Ratio | 31.06 |
| P/FCF Ratio | 59.65 |
| PEG Ratio | 2.14 |
Enterprise Valuation
IDEXX Laboratories Inc. has an Enterprise Value (EV) of 46.60B.
| EV / Earnings | 55.14 |
| EV / Sales | 12.73 |
| EV / EBITDA | 38.27 |
| EV / EBIT | 42.47 |
| EV / FCF | 60.29 |
Financial Position
The company has a current ratio of 1.57, with a Debt / Equity ratio of 0.64.
| Current Ratio | 1.57 |
| Quick Ratio | 1.17 |
| Debt / Equity | 0.64 |
| Total Debt / Capitalization | 38.97 |
| Cash Flow / Debt | 0.96 |
| Interest Coverage | 26.39 |
Financial Efficiency
Return on equity (ROE) is 0.57% and return on capital (ROIC) is 34.24%.
| Return on Equity (ROE) | 0.57% |
| Return on Assets (ROA) | 0.26% |
| Return on Capital (ROIC) | 34.24% |
| Revenue Per Employee | 332.81K |
| Profits Per Employee | 76.82K |
| Employee Count | 11.00K |
| Asset Turnover | 1.12 |
| Inventory Turnover | 3.87 |
Taxes
| Income Tax | 216.13M |
| Effective Tax Rate | 0.2 |
Stock Price Statistics
The stock price has increased by -20.12% in the last 52 weeks. The beta is 1.36, so IDEXX Laboratories 's price volatility has been higher than the market average.
| Beta | 1.36 |
| 52-Week Price Change | -20.12% |
| 50-Day Moving Average | 441.68 |
| 200-Day Moving Average | 486.23 |
| Relative Strength Index (RSI) | 51.84 |
| Average Volume (20 Days) | 615.95K |
Income Statement
In the last 12 months, IDEXX Laboratories had revenue of $3.66B and earned $845.04M in profits. Earnings per share was $10.17.
| Revenue | 3.66B |
| Gross Profit | 2.19B |
| Operating Income | 1.10B |
| Net Income | 845.04M |
| EBITDA | 1.22B |
| EBIT | 1.10B |
| Earnings Per Share (EPS) | 10.17 |
Balance Sheet
The company has $453.93M in cash and $1.07B in debt, giving a net cash position of -$613.42M.
| Cash & Cash Equivalents | 453.93M |
| Total Debt | 1.07B |
| Net Cash | -613.42M |
| Retained Earnings | 4.44B |
| Total Assets | 3.35B |
| Working Capital | 424.52M |
Cash Flow
In the last 12 months, operating cash flow was $906.51M and capital expenditures -$133.63M, giving a free cash flow of $772.88M.
| Operating Cash Flow | 906.51M |
| Capital Expenditures | -133.63M |
| Free Cash Flow | 772.88M |
| FCF Per Share | 9.3 |
Margins
Gross margin is 59.82%, with operating and profit margins of 29.97% and 23.08%.
| Gross Margin | 59.82% |
| Operating Margin | 29.97% |
| Pretax Margin | 28.99% |
| Profit Margin | 23.08% |
| EBITDA Margin | 33.26% |
| EBIT Margin | 29.97% |
| FCF Margin | 21.11% |
Dividends & Yields
IDXX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 2.35% |
| FCF Yield | 2.18% |
Analyst Forecast
The average price target for IDXX is $537.5, which is 24.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $537.5 |
| Price Target Difference | 24.4% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Stock Splits
The last stock split was on Jun 16, 2015. It was a forward split with a ratio of 2:1.
| Last Split Date | Jun 16, 2015 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 16.97 |
| Piotroski F-Score | 7 |